ASX-listed clinical-stage oncology company, PharmAust has pocketed $755,594 after the ATO accepted its application for a Research and Development rebate in recognition of the innovations under development by the company’s wholly owned subsidiaries, Epichem and Pitney Pharmaceuticals. PharmAust said it plans to plough the cash straight back into ongoing clinical trials of its therapeutics on humans and animals.
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 142nd Hazer Group $2.4m 143rd Mustera Property Group $2.3m 145th RemSense Technologies $2.2m 146th BauMart Holdings $2.2m 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX